Summary
Pfizer Inc. filed a Form 8-K on July 20, 2006, to report its financial results for the second quarter of 2006. The key takeaway for investors is the announcement of these quarterly results, which are detailed in an accompanying press release filed as an exhibit to this report. This filing provides an official update on the company's performance and financial condition during the period. Investors should review the press release (Exhibit 99) for specific details regarding revenue, earnings, and any forward-looking statements or management commentary on the company's performance and outlook. This 8-K serves as the formal mechanism for disseminating this crucial financial information to the public and the market.
Key Highlights
- 1Pfizer Inc. filed an 8-K on July 20, 2006, to report its second-quarter 2006 financial results.
- 2The financial results for the second quarter of 2006 were announced via a press release.
- 3The press release is included as Exhibit 99 to the 8-K filing.
- 4This filing is made pursuant to Item 2.02 (Results of Operations and Financial Condition) of Form 8-K.
- 5The report officially incorporates the press release by reference, making it a filed document.
- 6Investors can find detailed financial performance information for Q2 2006 within the press release.